CORDIS
EU research results

CORDIS

English EN
Targeting the metabolism-immune system connections in Cancer

Targeting the metabolism-immune system connections in Cancer

Objective

"Cancer cells show common features of profound metabolic changes and escape from the immune system, independently of their tissue of origin. These metabolic adaptations are not limited to glucose metabolism (the ""Warburg effect"") but are more general and affect several metabolic pathways in cancer cells as well as in the stroma, including immune cells. This network will explore how nutrients and hypoxia regulate the tumor-immune system interplay, and how this communication is controlled by oncogenes, metabolic regulators and current or potential drugs targeting metabolism.
Understanding how metabolism can affect tumor cells and the anti-cancer immune response represents a potential therapeutic intervention point that can be exploited to develop novel therapies and new diagnostic and prognostic markers. The development of therapies targeting cancer metabolism is hampered by: 1) the complexity of the regulation that metabolism exerts on many different tumor layers, which requires multidisciplinary collaborations, and 2) the shortage of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and complementary skills to convert research findings into commercial and clinical applications.
This network provides a pan-European interdisciplinary and intersectoral training program of excellence bringing young researchers together with World leading academics, clinicians, pharma industry members, corporate research and dissemination and outreach specialists. As part of the research training, the consortium will conduct a coherent and integrated set of hypothesis-driven research projects that are aimed at discovering, describing and exploiting how metabolism at the cell and the whole body levels is integrated with modulation of cell death susceptibility and the immune response in the context of cancer.
"
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Address

Avenida Gran Via Hospitalet 199-203
08908 L'Hospitalet De Llobregat

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 743 618,88

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 255 374,28

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 525 751,20

VIB

Belgium

EU Contribution

€ 501 120

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 260 300,52

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 511 868,16

IBM ISRAEL - SCIENCE AND TECHNOLOGY LTD

Israel

EU Contribution

€ 260 300,52

APPLIED RESEARCH USING OMIC SCIENCES SL

Spain

EU Contribution

€ 247 872,96

EVOTEC (FRANCE) SAS

France

EU Contribution

€ 262 875,60

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 262 875,60

Partners (7)

Sort alphabetically

Expand all

Seahorse Bio (Agilent Technologies)

Canceropole PACA

BIOcomuniCAT

HOSPITAL SANT JOAN DE DÉU

BOEHRINGER INGELHEIM RCV GMBH & CO KG

FUNDACION ESADE

The FEBS Journal (FEBS)

Project information

Grant agreement ID: 766214

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 831 957,72

  • EU contribution

    € 3 831 957,72

Coordinated by:

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain